Amicus agrees to be acquired by BioMarin for $14.50 per share in cash

AMICUS THERAPEUTICS, INC.

Merger consideration $14.50 per share; expected to close in Q2 2026.
Termination fee of $175M payable by Amicus in certain termination scenarios.
Transaction requires shareholder approval, HSR and foreign antitrust clearances.
No-solicit restrictions apply; Amicus board may consider superior proposals under fiduciary duty.
Bylaws amended to add exclusive forum provision (Item 5.03).

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

AMICUS THERAPEUTICS, INC.: On December 19, 2025, the Board approved and adopted a Forum Selection Amendment to the Company's existing By-laws, adding a new Section 6.5 to Article VI (effective 2025-12-19).

Change: bylaw amendment
Effective: 2025-12-19

Exact text from the filing

On December 19, 2025, the Board approved and adopted an amendment (the “ Forum Selection Amendment ”) to the Company’s existing By-laws that amends Article VI to include a new Section 6.5.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

AMICUS THERAPEUTICS, INC. entered into Agreement and Plan of Merger with BioMarin Pharmaceutical Inc. valued at $14.50 per Share in cash (effective 2025-12-19).

Action: entry
Agreement: merger
Counterparty: BioMarin Pharmaceutical Inc.
Value: $14.50 per Share in cash
Effective: 2025-12-19

Exact text from the filing

On December 19, 2025, Amicus Therapeutics, Inc. (the “ Company ” or “ Amicus ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with BioMarin Pharmaceutical Inc., a Delaware corporation (“ Parent ”), and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“ Merger Sub ”), providing for the merger of Merger Sub with and into the Company (the “ Merger ”),

View on SEC.gov

237 governance changes filed in the last 30 days. Browse all governance changes →

Source: SEC EDGAR

accession 0001140361-25-046134

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.